```
=> b reg
FILE 'REGISTRY' ENTERED AT 17:34:29 ON 02 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 OCT 2008  HIGHEST RN 1056151-32-6
DICTIONARY FILE UPDATES:   1 OCT 2008  HIGHEST RN 1056151-32-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l12
L8              STR
```




```
REP G1=(0-19) A
VAR G2=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E3 C  E2 N  AT   1
ECOUNT  IS E8 C  E1 O  AT  11

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  11

STEREO ATTRIBUTES: NONE
L10       11255 SEA FILE=REGISTRY ABB=ON  PLU=ON  (NCNC2 OR N2C3)/ES AND
                OC4-C6/ES
L12          76 SEA FILE=REGISTRY SUB=L10 SSS FUL L8

100.0% PROCESSED    2253 ITERATIONS                          76 ANSWERS
SEARCH TIME: 00.00.01



=> b hcap
FILE 'HCAPLUS' ENTERED AT 17:34:34 ON 02 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
```

strictly prohibited.

FILE COVERS 1907 - 2 Oct 2008 VOL 149 ISS 14
FILE LAST UPDATED: 1 Oct 2008 (20081001/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs hitrn fhitstr l17 tot

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:1009620 HCAPLUS
DN 149:283036
TI Therapeutic agent for diabetic cataract
IN Ishii, Kunio; Saito, Maki
PA School Juridical Person Kitasato Institute, Japan
SO PCT Int. Appl., 67pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2008099804	A1	20080821	2008WO-JP0052239	20080212
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
JP--2008195655	A	20080828	2007JP-000032923	20070214
PRAI 2007JP-000032923	A	20070214		

AB Disclosed is a therapeutic agent for diabetic cataract which has effective delay activity on the progress of diabetic cataract. The therapeutic agent comprises an antioxidant agent capable of preventing the impaired oxidation in the retina as an active ingredient. The antioxidant agent may be a phenylazole compound having a specific structure or a pharmaceutically acceptable salt thereof. It is found that an antioxidant agent having a NO radical scavenging activity and a high penetration into a cornea has an efficient anti-diabetic cataract activity. Based on this finding, it becomes possible to provide a novel therapeutic strategy for cataract which has been considered to be hardly treated by drug therapy so far.
IT 841294-26-6P 841294-27-7P 841294-38-0P
841294-39-1P 841294-42-6P 841294-43-7P
841294-44-8P 841294-45-9P 841294-48-2P
841294-49-3P 841294-50-6P 841294-51-7P
841294-54-0P 841294-55-1P 841294-56-2P
841294-57-3P 841294-58-4P 841294-60-8P
841294-61-9P 841294-62-0P 841295-82-7P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylazole derivs. as therapeutic agents for diabetic cataract)
IT 841295-42-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(phenylazole derivs. as therapeutic agents for diabetic cataract)
IT 841294-26-6P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylazole derivs. as therapeutic agents for diabetic cataract)
RN 841294-26-6 HCAPLUS
CN 5-Benzofuranamine, 2,3-dihydro-2-{[4-[4-(1H-imidazol-1-yl)phenyl]-1-piperazinyl]methyl}-2,4,6,7-tetramethyl- (CA INDEX NAME)

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:120922 HCAPLUS
DN 142:219317
TI Preparation of phenylazole derivatives as antioxidants
IN Umeda, Nobuhiro; Mochiduki, Nobuo; Uchida, Seiichi; Takada, Mitsumasa; Ikeyama, Seiichi; Tsubokura, Shiro; Shiinoki, Yasuyuki; Shirato, Fumie; Moroe, Hiroko
PA Nippon Soda Co., Ltd., Japan
SO PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005012293	A1	20050210	2004WO-JP0011297	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2004260758	A1	20050210	2004AU-0002607S8	20040730
AU--2004260758	B2	20070607		
CA-----2534263	A1	20050210	2004CA-002534263	20040730
EP-----1650206	A1	20060426	2004EP-000748268	20040730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US-20060247228	A1	20061102	2006US-000566820	20060130
PRAI 2003JP-000285421	A	20030801		
2003JP-000291881	A	20030811		
2003JP-000298443	A	20030822		
2004JP-000022958	A	20040130		
2004JP-000023903	A	20040130		
2004JP-000023971	A	20040130		
2004WO-JP0011297	W	20040730		

OS MARPAT 142:219317
GI



AB The title compds. BDZ [B is I, etc.; A is optionally substituted imidazolyl or pyrazolyl; R1 is (un)substituted alkyl, etc.; m is 0 or 1 - 4; X is O, etc.; D is oxygen, sulfur, etc.; Z is NHR10- or OR11-substituted chroman-2-yl, chroman-4-yl, etc.; R10 is H, alkylcarbonyl, etc.; R11 is H, alkylcarbonyl, etc.] are prepared The title compds. are useful in the treatment of cerebrovascular disorder, etc. Thus, 4-(tr)-(5-amino-2,4,6,7-tetramethyldihydrobenzofuran-2-ylmethyl)-1-(4-imidazol-1-ylphenyl)piperazine was prepared in a multistep process from 1-acetyl-4-(4-bromophenyl)piperazine and imidazole. A formulation is given.
IT 841294-26-6P 841294-27-7P 841294-28-8P
841294-38-0P 841294-39-1P 841294-42-6P
841294-43-7P 841294-44-8P 841294-45-9P
841294-48-2P 841294-49-3P 841294-50-6P
841294-51-7P 841294-54-0P 841294-55-1P
841294-56-2P 841294-57-3P 841294-58-4P
841294-60-8P 841294-61-9P 841294-62-0P
841294-74-4P 841294-76-6P 841294-77-7P
841294-78-8P 841294-79-9P 841294-80-2P

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
841294-81-3P 841294-82-4P 841294-83-5P
841294-84-6P 841295-82-7P 841298-43-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylazole derivs. as antioxidants)
IT 841295-41-8P 841295-42-9P 841295-46-3P
841295-50-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylazole derivs. as antioxidants)
IT 841294-26-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylazole derivs. as antioxidants)
RN 841294-26-6 HCAPLUS
CN 5-Benzofuranamine, 2,3-dihydro-2-{[4-[4-(1H-imidazol-1-yl)phenyl]-1-piperazinyl]methyl}-2,4,6,7-tetramethyl- (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d bib abs hitrn hitstr l18 tot
```

L18 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:1009620 HCAPLUS
DN 149:283036
TI Therapeutic agent for diabetic cataract
IN Ishii, Kunio; Saito, Maki
PA School Juridical Person Kitasato Institute, Japan
SO PCT Int. Appl., 67pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2008099804	A1	20080821	2008WO-JP0052239	20080212
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	JP--2008195655	A	20080828	2007JP-000032923	20070214
PRAI	2007JP-000032923	A	20070214		

AB Disclosed is a therapeutic agent for diabetic cataract which has effective delay activity on the progress of diabetic cataract. The therapeutic agent comprises an antioxidant agent capable of preventing the impaired oxidation in the retina as an active ingredient. The antioxidant agent may be a phenylazole compound having a specific structure or a pharmaceutically acceptable salt thereof. It is found that an antioxidant agent having a NO radical scavenging activity and a high penetration into a cornea has an efficient anti-diabetic cataract activity. Based on this finding, it becomes possible to provide a novel therapeutic strategy for cataract which has been considered to be hardly treated by drug therapy so far.

IT 1048370-27-9P 1048370-30-4P 1048370-31-5P
1048370-34-8P 1048370-35-9P 1048370-36-0P
1048370-38-2P 1048370-39-3P 1048370-40-6P
1048370-41-7P 1048370-44-0P 1048370-45-1P
1048370-48-4P 1048370-51-9P 1048370-52-0P
1048370-53-1P 1048370-55-3P 1048370-58-6P
1048370-59-7P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylazole derivs. as therapeutic agents for diabetic cataract)

IT 1048370-27-9P 1048370-30-4P 1048370-31-5P
1048370-34-8P 1048370-35-9P 1048370-36-0P
1048370-38-2P 1048370-39-3P 1048370-40-6P
1048370-41-7P 1048370-44-0P 1048370-45-1P
1048370-48-4P 1048370-51-9P 1048370-52-0P
1048370-53-1P 1048370-55-3P 1048370-58-6P
1048370-59-7P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylazole derivs. as therapeutic agents for diabetic cataract)

RN 1048370-27-9 HCAPLUS
CN Methanone, (2,3-dihydro-5-hydroxy-2,4,6,7-tetramethyl-2-benzofuranyl){4-[3-(1H-imidazol-1-yl)phenyl]-1-piperazinyl}- (CA INDEX NAME)

L18 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN 5-Benzofuranol, 2,3-dihydro-2,4,6,7-tetramethyl-2-[{4-[4-(1H-pyrazol-3-yl)phenyl]-1-piperazinyl}methyl]- (CA INDEX NAME)



RN 1048370-38-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1048370-39-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1048370-40-6 HCAPLUS
CN Methanone, {5-(acetyloxy)-2,3-dihydro-2,4,6,7-tetramethyl-2-benzofuranyl}{4-[4-(1H-pyrazol-3-yl)phenyl]-1-piperazinyl}- (CA INDEX NAME)



RN 1048370-41-7 HCAPLUS
CN 5-Benzofuranol, 2,3-dihydro-2,4,6,7-tetramethyl-2-[{4-[4-(1H-pyrazol-3-yl)phenyl]-1-piperazinyl}methyl]-, 5-acetate (CA INDEX NAME)



RN 1048370-44-0 HCAPLUS

L18 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1048370-30-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1048370-31-5 HCAPLUS
CN Methanone, {5-(acetyloxy)-2,3-dihydro-2,4,6,7-tetramethyl-2-benzofuranyl}{4-[3-(1H-imidazol-1-yl)phenyl]-1-piperazinyl}- (CA INDEX NAME)



RN 1048370-34-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1048370-35-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1048370-36-0 HCAPLUS

L18 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN INDEX NAME NOT YET ASSIGNED



RN 1048370-45-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1048370-48-4 HCAPLUS
CN 5-Benzofuranol, 2,3-dihydro-2,4,6,7-tetramethyl-2-[[4-[3-(1H-pyrazol-3-yl)phenyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 1048370-51-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1048370-52-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1048370-53-1 HCAPLUS
CN Methanone, {5-(acetyloxy)-2,3-dihydro-2,4,6,7-tetramethyl-2-benzofuranyl}{4-[3-(1H-pyrazol-3-yl)phenyl]-1-piperazinyl}- (CA INDEX NAME)

L18 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1048370-55-3 HCAPLUS
CN 5-Benzofuranol, 2,3-dihydro-2,4,6,7-tetramethyl-2-[[4-[3-(1H-pyrazol-3-yl)phenyl]-1-piperazinyl]methyl]-, 5-acetate (CA INDEX NAME)



RN 1048370-58-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1048370-59-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:509811 HCAPLUS
DN 146:500879
TI Preparation of aminobenzofurans and related compounds as antioxidant drugs
IN Tsubokura, Shiro; Umeda, Nobuhiro; Uchida, Seiichi
PA Nippon Soda Co., Ltd., Japan
SO PCT Int. Appl., 55pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2007052794	A1	20070510	2006WO-JP0322111	20061106
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU--2006309576	A1	20070510	2006AU-000309576	20061106
	CA-----2628014	A1	20070510	2006CA-002628014	20061106
	EP-----1944024	A1	20080716	2006EP-000823024	20061106
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	KR--2008053950	A	20080616	2008KR-000710495	20080430
PRAI	2005JP-000321612	A	20051104		
	2006WO-JP0322111	W	20061106		

OS MARPAT 146:500879
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [a = 1, 2; R0 = (un)substituted amino; R1-R4 = H, alkyl; E = (un)substituted alkylene; D = single bond, oxygen, (un)substituted nitrogen, etc.; A = (un)substituted aromatic hydrocarbon, (un)substituted heterocycle, (un)substituted aralkyl, etc.] and their salts were prepared For example, treatment of 2,2,6,7-tetramethyl-4-nitromethyl-5-nitrodihydrobenzofuran with KMnO4 followed by reductive amination with 1-[4-(imidazol-1-yl)phenylmethyl]piperazine and reduction using Zn powder afforded compound II. In peroxidized lipid formation-inhibiting test, compound II showed the IC50 value of 0.37 μM. Compds. I are claimed useful for the treatment of kidney diseases, cerebrovascular diseases, etc.
IT 936214-34-5P 936214-35-6P 936214-36-7P
936214-37-8P 936214-38-9P 936215-02-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminobenzofurans and related compds. as antioxidant drugs)
IT 936214-91-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminobenzofurans and related compds. as antioxidant drugs)
IT 936214-34-5P 936214-35-6P 936214-36-7P
936214-37-8P 936214-38-9P 936215-02-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminobenzofurans and related compds. as antioxidant drugs)
RN 936214-34-5 HCAPLUS

L18 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 5-Benzofuranamine, 2,3-dihydro-4-[[4-[[4-(1H-imidazol-1-yl)phenyl]-1-piperazinyl]methyl]-2,2,6,7-tetramethyl- (CA INDEX NAME)



RN 936214-35-6 HCAPLUS
CN 5-Benzofuranamine, 2,3-dihydro-4-[[4-[[4-(1H-imidazol-1-yl)phenyl]methyl]-1-piperazinyl]methyl]-2,2,6,7-tetramethyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 936214-36-7 HCAPLUS
CN 5-Benzofuranamine, 2,3-dihydro-2,2,6,7-tetramethyl-4-[[4-[[4-(1H-pyrazol-3-

L18 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
yl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 936214-37-8 HCAPLUS
CN 5-Benzofuranamine, 2,3-dihydro-2,2,6,7-tetramethyl-4-[[4-[4-(1H-pyrazol-3-yl)phenyl]-1-piperidinyl]methyl]- (CA INDEX NAME)



RN 936214-38-9 HCAPLUS
CN 5-Benzofuranamine, 2,3-dihydro-2,2,6,7-tetramethyl-4-[[4-[4-(1H-pyrazol-1-

L18 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
yl)phenyl]-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 936215-02-0 HCAPLUS
CN 5-Benzofuranamine, 4-[[3,6-dihydro-4-[4-(1H-pyrazol-1-yl)phenyl]-1(2H)-pyridinyl]methyl]-2,3-dihydro-2,2,6,7-tetramethyl- (CA INDEX NAME)



IT 936214-91-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminobenzofurans and related compds. as antioxidant drugs)
RN 936214-91-4 HCAPLUS
CN Piperazine, 1-[(2,3-dihydro-2,2,6,7-tetramethyl-5-nitro-4-benzofuranyl)methyl]-4-[[4-(1H-imidazol-1-yl)phenyl]methyl]- (CA INDEX NAME)

L18 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:83522 HCAPLUS
DN 146:184485
TI Preparation of nitrogen-containing heterocycles as antioxidants and their pharmaceutical uses
IN Umeda, Nobuhiro; Uchida, Seiichi
PA Nippon Soda Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 67pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP--2007016011	A	20070125	2005JP-000274409	20050921
PRAI 2005JP-000171150	A	20050610		

OS MARPAT 146:184485
GI



I

AB Title compds. I [R1 = (un)substituted C1-6 alkyl; l = 0-10; m = 1, 2; Q = (un)substituted benzoheterocyclyl, tetralin analogs, etc.; the dotted line may be single or double bond; Y = (un)substituted C, N; D = O, S, (CO)j(NR6)k(CR7R8)h; R6 = H, C1-6 alkylcarbonyl, (un)substituted Bz; R7, R8 = H, cyano, OH, halo, C1-6 alkyl(oxy), C2-6 alkenyl(oxy), etc.; j, k = 0, 1; h = 0-16; E = substituted chroman-2 or 4-yl, 2,3-dihydrobenzofuran-2- or 3-yl, thiochroman-2- or 4-yl, etc.) or their salts are prepared and useful for treatment of renal, cerebrovascular, and circulation disorders, cerebral infarction, and diabetic retinopathy. Thus, N-(1,2,3,4-tetrahydronaphthalen-1-yl)piperazine was condensed with 2,4,6,7-tetramethyl-5-nitrodihydrobenzofuran-2-yl trifluoromethanesulfonate and treated with SnCl2 to give the corresponding amine, which inhibited lipid peroxide formation with IC50 value of 0.21 μM in vitro and 15 mg/kg p.o. in rats, resp.
IT 921230-30-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocycles as antioxidants for treatment of renal, cerebrovascular, and circulation disorders and diabetic retinopathy)
IT 921230-30-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocycles as antioxidants for treatment of renal, cerebrovascular, and circulation disorders and diabetic retinopathy)
RN 921230-30-0 HCAPLUS
CN 5-Benzofuranamine, 2-[[4-[2,3-dihydro-5-(1H-imidazol-1-yl)-1H-inden-1-yl]-1-piperazinyl]methyl]-2,3-dihydro-2,4,6,7-tetramethyl- (CA INDEX NAME)



L18 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:256243 HCAPLUS
DN 136:294851
TI Preparation of piperazine (hetero)aryl ketones and sulfones as factor Xa inhibitors for treatment of thrombosis or coagulation disorders
IN Zhu, Bing-Yan; Jia, Zhaozhong Jon; Zhang, Penglie; Huang, Wenrong; Wu, Yanhong; Zuckett, Jingmei Fan; Goldman, Erik A.; Wang, Lingyan; Song, Yonghong; Scarborough, Robert M.
PA Cor Therapeutics, Inc., USA
SO PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2002026720	A2	20020404	2001WO-US0030315	20011001
WO--2002026720	A3	20021031		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2001094824	A	20020408	2001AU-000094824	20011001
EP-----1322610	A2	20030702	2001EP-000975505	20011001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US-20040082786	A1	20040429	2003US-000381928	20031016
PRAI 2000US-00236161P	P	20000929		
2001WO-US0030315	W	20011001		

OS MARPAT 136:294851
GI



I



II

AB Title compds. I [wherein A = (un)substituted imidazolinyl, tetrahydropyrimidinyl, tetrahydro-1H-1,3-diazepinyl, imidamido(alkyl), guanidinyl, amino(alkyl), ammoniomethyl, Ph, pyridinyl, etc.; Q = (un)substituted phenylene, pyrimidinediyl, pyridinediyl, pyrazinediyl, pyrroledilyl, furandiyl, thiophenediyl, piperidinediyl, or pyrrolidinediyl; V = CH2 or CO; G = CO or SO2; J = (un)substituted naphthyl, (iso)quinolinyl, quinazolinyl, indolyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, etc.; R1 and R2 = independently H, alkyl, hydroxyalkyl, aminoalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, or carbamoylalkyl; and pharmaceutically acceptable isomers, salts, hydrates, solvates, and prodrugs thereof] were prepared For example, 1-Boc-5-chloro-2-indolylsulfonyl chloride was coupled with 1-Boc-piperazine in DCM in the presence of pyridine to give the sulfonamide (95%). Deprotection using HCl gas (99%), followed by acylation with 4-cyanobenzoyl chloride in pyridine in the presence of DMAP (73%) and treatment with HCl and dimethylamine, afforded II. I are highly selective inhibitors of factor Xa and are useful for the treatment of diseases characterized by undesired thrombosis or coagulation disorders

L18 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(no data).
IT 406719-55-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(factor Xa inhibitor; preparation of piperazine (hetero)aryl ketones and sulfones as factor Xa inhibitors for treatment of thrombosis or coagulation disorders)
IT 406719-55-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(factor Xa inhibitor; preparation of piperazine (hetero)aryl ketones and sulfones as factor Xa inhibitors for treatment of thrombosis or coagulation disorders)
RN 406719-55-9 HCAPLUS
CN Piperazine, 1-[(5-chloro-2-benzofuranyl)carbonyl]-4-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)benzoyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:723030 HCAPLUS
DN 131:322629
TI Preparation of 1-heteroarylsulfonyl-4-heteroarylbenzoylpiperazines and analogs as Factor Xa inhibitors
IN Caulkett, Peter William Rodney; James, Roger; Pearson, Stuart Eric; Slater, Anthony Michael; Walker, Rolf Peter
PA Zeneca Limited, UK
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-----9957113	A1	19991111	1999WO-GB0001308	19990427
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA-----2331042	A1	19991111	1999CA-002331042	19990427
AU-----9936206	A	19991123	1999AU-000036206	19990427
AU------754453	B2	20021114		
BR-----9910179	A	20010109	1999BR-000010179	19990427
TR---200003200	T2	20010221	2000TR-000003200	19990427
EP-----1082321	A1	20010314	1999EP-000918178	19990427
EP-----1082321	B1	20041117		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU--2001001712	A2	20011128	2001HU-000001712	19990427
HU--2001001712	A3	20030128		
EE---200000527	A	20020215	2000EE-000000527	19990427
NZ------507835	A	20030131	1999NZ-000507835	19990427
CN-----1133634	C	20040107	1999CN-000808218	19990427
RU-----2225865	C2	20040320	2000RU-000130219	19990427
IL------139406	A	20040725	1999IL-000139406	19990427
AT------282610	T	20041215	1999AT-000918178	19990427
PT-----1082321	T	20050331	1999PT-000918178	19990427
EP-----1528061	A1	20050504	2004EP-000022155	19990427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
ES-----2232131	T3	20050516	1999ES-000918178	19990427
IN---199900659	A	20050701	1999IN-000000659	19990429
ZA---2000006031	A	20020125	2000ZA-000006031	20001025
MX-2000PA10675	A	20000821	2000MX-PA0010675	20001030
NO---2000005497	A	20001221	2000NO-000005497	20001101
NO------320893	B1	20060206		
US-----6753331	B1	20040622	2001US-000674559	20010104
HK-----1034711	A1	20050513	2001HK-000105226	20010726
US-20040266759	A1	20041230	2004US-000817960	20040406
PRAI 1998GB-000009351	A	19980502		
1999GB-000003337	A	19990216		
1999EP-000918178	A3	19990427		
1999WO-GB0001308	W	19990427		
2001US-000674559	A1	20010104		

OS MARPAT 131:322629
GI

L18 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I

AB RZCOZ1SO2R1 [R = (un)substituted heteroaryl; R1 = (un)substituted 2-indolyl, -2-benzimidazolyl, -2-benzo[b]furanyl, etc.; Z = (un)substituted 1,4-phenylene; Z1 = (un)substituted piperidine-4,1-diyl or -piperazine-1,4-diyl] were prepared Thus, 5-chlorobenzo[b]furan-2-sulfonyl chloride was amidated by piperazine and the product amidated by 4-(4-pyridyl)benzoic acid to give title compound I. Data for biol. activity of I were given.
IT 249292-01-1P 249292-19-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-heteroarylsulfonyl-4-heteroarylbenzoylpiperazines and analogs as Factor Xa inhibitors)
IT 249292-01-1P 249292-19-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-heteroarylsulfonyl-4-heteroarylbenzoylpiperazines and analogs as Factor Xa inhibitors)
RN 249292-01-1 HCAPLUS
CN Methanone, [4-[(5-chloro-2-benzofuranyl)sulfonyl]-1-piperazinyl][4-(1H-imidazol-1-yl)phenyl]- (CA INDEX NAME)



RN 249292-19-1 HCAPLUS
CN Methanone, [4-[(5-chloro-2-benzofuranyl)sulfonyl]-1-piperazinyl][4-(2-methyl-1H-imidazol-5-yl)phenyl]- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 17:35:08 ON 02 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:35:08 ON 02 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:35:08 ON 02 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l20 tot
```

L20 ANSWER 1 OF 2 USPATFULL on STN
AN 2007:120056 USPATFULL
TI Multi-Transmitter Interference Suppression Using Code-Specific Combining
IN Bottomley, Gregory E., 100 Merlot Court, Cary, NC, UNITED STATES 27511
Wang, Yi-Pin Eric, 215 Cedarpost Drive, Cary, NC, UNITED STATES 27513
PI US-20070104254 A1 20070510
AI 2006US-000566820 A1 20061205 (11)
RLI Continuation-in-part of Ser. No. 2003US-000720492, filed on 24 Nov 2003, PENDING
DT Utility
FS APPLICATION
LREP COATS & BENNETT, PLLC, 1400 Crescent Green, Suite 300, Cary, NC, 27518, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 616
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Multi-transmitter interference caused by one or more interfering own-cell and/or other-cell transmitters is reduced in a RAKE-based receiver. The RAKE-based receiver comprises a plurality of RAKE fingers, a processor and a combiner. The plurality of RAKE fingers are configured to despread received symbols, wherein a delay for a first one of the plurality of RAKE fingers corresponds to a symbol of interest transmitted by a first transmitter and a delay for a second one of the plurality of RAKE fingers corresponds to an interfering symbol transmitted by a second transmitter. The processor is configured to determine a cross-correlation between the symbol of interest and the interfering symbol. The combiner is configured to combine the symbol of interest with the interfering symbol using the cross-correlation to reduce interference attributable to the interfering symbol from the symbol of interest.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 841294-26-6P 841294-27-7P 841294-28-8P
841294-38-0P 841294-39-1P 841294-42-6P
841294-43-7P 841294-44-8P 841294-45-9P
841294-48-2P 841294-49-3P 841294-50-6P
841294-51-7P 841294-54-0P 841294-55-1P
841294-56-2P 841294-57-3P 841294-58-4P
841294-60-8P 841294-61-9P 841294-62-0P
841294-74-4P 841294-76-6P 841294-77-7P
841294-78-8P 841294-79-9P 841294-80-2P
841294-81-3P 841294-82-4P 841294-83-5P
841294-84-6P 841295-82-7P 841298-43-9P
(preparation of phenylazole derivs. as antioxidants)
IT 841295-41-8P 841295-42-9P 841295-46-3P
841295-50-9P
(preparation of phenylazole derivs. as antioxidants)
IT 841294-26-6P
(preparation of phenylazole derivs. as antioxidants)
RN 841294-26-6 USPATFULL
CN 5-Benzofuranamine, 2,3-dihydro-2-[[4-[4-(1H-imidazol-1-yl)phenyl]-1-piperazinyl]methyl]-2,4,6,7-tetramethyl- (CA INDEX NAME)



L20 ANSWER 2 OF 2 USPATFULL on STN (Continued)



L20 ANSWER 2 OF 2 USPATFULL on STN
AN 2006:289234 USPATFULL
TI Phenylazole compounds production process and antioxidants
IN Umeda, Nobuhiro, Kanagawa-ken, JAPAN
Mochizuki, Nobuo, Kanagawa-ken, JAPAN
Uchida, Seiichi, Kanagawa-ken, JAPAN
Takada, Mitsumasa, Kanagawa-ken, JAPAN
Tsubokura, Shiro, Kanagawa-ken, JAPAN
Shiinoki, Yasuyuki, Kanagawa-ken, JAPAN
Shirato, Fumie, Kanagawa-ken, JAPAN
Moroe, Hiroko, Kanagawa-ken, JAPAN
PA Nippon Soda Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US-20060247228 A1 20061102
AI 2004US-000566820 A1 20040730 (10)
2004WO-JP0011297 20040730
20060130 PCT 371 date
PRAI 2003JP-000285421 20030801
2003JP-000291881 20030811
2003JP-000298443 20030822
2004JP-000022958 20040130
2004JP-000023903 20040130
2004JP-000023971 20040130
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4779
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds represented by the formula (1): B-D-Z (1) [wherein B represent the following formula (B-1), (B-2) or (B-3); ##STR1## A represents an optionally substituted imidazole or pyrazole group; E represents the following formula (1a): ##STR2## X represents an oxygen atom, the formula: SOu, or the formula: N--R.sub.9; Y represents a carbon atom or a nitrogen atom; D represents an oxygen atom, a sulfur atom or the formula (1a)] Z represents (a chroman-2-yl group, a chroman-4-yl group, a 2,3-dihydrobenzofuran-2-yl group, a 2,3-dihydrobenzofuran-3-yl group, etc.) which is substituted with NHR.sub.10 or OR.sub.11)] or pharmaceutically acceptable salts thereof, and to antioxidants, therapeutic agents for kidney diseases or cerebrovascular disorder, and retinal oxidative damage inhibitors, which include the compounds as the active ingredient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 841294-26-6P 841294-27-7P 841294-28-8P
841294-38-0P 841294-39-1P 841294-42-6P
841294-43-7P 841294-44-8P 841294-45-9P
841294-48-2P 841294-49-3P 841294-50-6P
841294-51-7P 841294-54-0P 841294-55-1P
841294-56-2P 841294-57-3P 841294-58-4P
841294-60-8P 841294-61-9P 841294-62-0P
841294-74-4P 841294-76-6P 841294-77-7P
841294-78-8P 841294-79-9P 841294-80-2P
841294-81-3P 841294-82-4P 841294-83-5P
841294-84-6P 841295-82-7P 841298-43-9P
(preparation of phenylazole derivs. as antioxidants)
IT 841295-41-8P 841295-42-9P 841295-46-3P
841295-50-9P
(preparation of phenylazole derivs. as antioxidants)
IT 841294-26-6P
(preparation of phenylazole derivs. as antioxidants)
RN 841294-26-6 USPATFULL
CN 5-Benzofuranamine, 2,3-dihydro-2-[[4-[4-(1H-imidazol-1-yl)phenyl]-1-piperazinyl]methyl]-2,4,6,7-tetramethyl- (CA INDEX NAME)

=> d bib abs hitstr l21 tot

L21 ANSWER 1 OF 3 USPATFULL on STN
AN 2004:335665 USPATFULL
TI Heterocyclic derivatives which inhibit factor Xa
IN Caulkett, Peter W.R., Macclesfield, UNITED KINGDOM
James, Roger, Macclesfield, UNITED KINGDOM
Pearson, Stuart E., Macclesfield, UNITED KINGDOM
Slater, Anthony M., Macclesfield, UNITED KINGDOM
Walker, Rolf P., Macclesfield, UNITED KINGDOM
PA AstraZeneca AB (non-U.S. corporation)
PI US-20040266759 A1 20041230
AI 2004US-000817960 A1 20040406 (10)
RLI Continuation of Ser. No. 2001US-000674559, filed on 4 Jan 2001, GRANTED, Pat. No. US-----6753331 A 371 of International Ser. No. 1999WO-GB0001308, filed on 27 Apr 1999, UNKNOWN
PRAI 1998GB-000009351 19980502
1999GB-000003337 19990216
DT Utility
FS APPLICATION
LREP MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1164
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heterocyclic derivatives of formula (I), or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 249292-01-1P 249292-19-1P
(preparation of 1-heteroarylsulfonyl-4-heteroarylbenzoylpiperazines and analogs as Factor Xa inhibitors)
RN 249292-01-1 USPATFULL
CN Methanone, [4-[(5-chloro-2-benzofuranyl)sulfonyl]-1-piperazinyl][4-(1H-imidazol-1-yl)phenyl]- (CA INDEX NAME)



RN 249292-19-1 USPATFULL
CN Methanone, [4-[(5-chloro-2-benzofuranyl)sulfonyl]-1-piperazinyl][4-(2-methyl-1H-imidazol-5-yl)phenyl]- (CA INDEX NAME)



L21 ANSWER 2 OF 3 USPATFULL on STN
AN 2004:154490 USPATFULL
TI Heterocyclic derivatives which inhibit factor Xa
IN Caulkett, Peter WR, Macclesfield, UNITED KINGDOM
James, Roger, Macclesfield, UNITED KINGDOM
Pearson, Stuart E, Macclesfield, UNITED KINGDOM
Slater, Anthony M, Macclesfield, UNITED KINGDOM
Walker, Rolf P, Macclesfield, UNITED KINGDOM
PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US-----6753331 B1 20040622
WO-----9957113 19991111
AI 2001US-000674559 20010104 (9)
1999WO-GB0001308 19990427
PRAI 1998GB-000009351 19980502
1999GB-000003337 19990216
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.
LREP Morgan, Lewis & Bockius, LLP
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1058
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heterocyclic derivatives of formula (I), or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 249292-01-1P 249292-19-1P
(preparation of 1-heteroarylsulfonyl-4-heteroarylbenzoylpiperazines and analogs as Factor Xa inhibitors)
RN 249292-01-1 USPATFULL
CN Methanone, [4-[(5-chloro-2-benzofuranyl)sulfonyl]-1-piperazinyl][4-(1H-imidazol-1-yl)phenyl]- (CA INDEX NAME)



RN 249292-19-1 USPATFULL
CN Methanone, [4-[(5-chloro-2-benzofuranyl)sulfonyl]-1-piperazinyl][4-(2-methyl-1H-imidazol-5-yl)phenyl]- (CA INDEX NAME)



L21 ANSWER 3 OF 3 USPATFULL on STN
AN 2004:108384 USPATFULL
TI Piperazine based inhibitors of factor xa
IN Zhu, Bing-Yan, Palo Alto, CA, UNITED STATES
Jia, Zhaozhong Jon, San Mateo, CA, UNITED STATES
Zhang, Penglie, Foster City, CA, UNITED STATES
Huang, Wenrong, Cupertino, CA, UNITED STATES
Wu, Yanhong, Foster City, CA, UNITED STATES
Zuckett, Jingmei Fan, Bellevue, MA, UNITED STATES
Goldman, Erik A., Berkeley, CA, UNITED STATES
Wang, Lingyan, East Brunswick, NJ, UNITED STATES
Song, Younghong, Foster City, CA, UNITED STATES
Scarborough, Robert M., Half Moon Bay, CA, UNITED STATES
PI US-20040082786 A1 20040429
AI 2003US-000381928 A1 20031016 (10)
2001WO-US0030315 20011001
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1952
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel compounds of the general formulae (I) or (II), including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and the compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 406719-55-9P
(factor Xa inhibitor; preparation of piperazine (hetero)aryl ketones and sulfones as factor Xa inhibitors for treatment of thrombosis or coagulation disorders)
RN 406719-55-9 USPATFULL
CN Piperazine, 1-[(5-chloro-2-benzofuranyl)carbonyl]-4-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)benzoyl]- (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 17:15:34 ON 02 OCT 2008)

     FILE 'HCAPLUS' ENTERED AT 17:15:48 ON 02 OCT 2008
L1             1 US20060247228/PN

     FILE 'REGISTRY' ENTERED AT 17:15:55 ON 02 OCT 2008

     FILE 'HCAPLUS' ENTERED AT 17:16:02 ON 02 OCT 2008
L2               TRA L1 1- RN :      165 TERMS

     FILE 'REGISTRY' ENTERED AT 17:16:03 ON 02 OCT 2008
L3           165 SEA L2
L4           123 L3 AND (NCNC2 OR N2C3)/ES
L5           121 L4 AND C6/ES
L6            88 L5 AND OC4-C6/ES
L7            37 L6 AND (NC2NC2 OR NC5)/ES
L8               STR
L9             0 L8
L10        11255 (NCNC2 OR N2C3)/ES AND OC4-C6/ES
L11            2 L8 SAM SUB=L10
L12           76 L8 FULL SUB=L10
                 SAV TEM J820C1A/A L12
L13           37 L12 AND L3
L14           39 L12 NOT L13

     FILE 'HCAOLD' ENTERED AT 17:26:49 ON 02 OCT 2008
L15            0 L13
L16            0 L14

     FILE 'HCAPLUS' ENTERED AT 17:26:59 ON 02 OCT 2008
L17            2 L13
L18            5 L14
                 SEL HIT RN 4-5

     FILE 'REGISTRY' ENTERED AT 17:28:53 ON 02 OCT 2008
L19            3 E1-3

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 17:33:47 ON 02 OCT 2008
L20            2 L13
L21            3 L14

=>
```